DE60321142D1 - Zur erhöhung der konzentration von radioaktivem biotin bei der pretargeted radioimmuntherapie wirksame avidindimere - Google Patents

Zur erhöhung der konzentration von radioaktivem biotin bei der pretargeted radioimmuntherapie wirksame avidindimere

Info

Publication number
DE60321142D1
DE60321142D1 DE60321142T DE60321142T DE60321142D1 DE 60321142 D1 DE60321142 D1 DE 60321142D1 DE 60321142 T DE60321142 T DE 60321142T DE 60321142 T DE60321142 T DE 60321142T DE 60321142 D1 DE60321142 D1 DE 60321142D1
Authority
DE
Germany
Prior art keywords
radioimmun
avidindimers
pretargeted
concentration
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60321142T
Other languages
English (en)
Inventor
Santis Rita De
Ragnar Lindstedt
Carlo Antonio Nuzzolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE60321142D1 publication Critical patent/DE60321142D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60321142T 2002-03-08 2003-03-06 Zur erhöhung der konzentration von radioaktivem biotin bei der pretargeted radioimmuntherapie wirksame avidindimere Expired - Lifetime DE60321142D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002RM000128A ITRM20020128A1 (it) 2002-03-08 2002-03-08 Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".
PCT/IT2003/000135 WO2003075960A1 (en) 2002-03-08 2003-03-06 Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy

Publications (1)

Publication Number Publication Date
DE60321142D1 true DE60321142D1 (de) 2008-07-03

Family

ID=11456156

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60321142T Expired - Lifetime DE60321142D1 (de) 2002-03-08 2003-03-06 Zur erhöhung der konzentration von radioaktivem biotin bei der pretargeted radioimmuntherapie wirksame avidindimere

Country Status (22)

Country Link
US (2) US7425317B2 (de)
EP (1) EP1482981B1 (de)
JP (1) JP4362376B2 (de)
KR (1) KR100993626B1 (de)
CN (1) CN1638807B (de)
AR (1) AR038897A1 (de)
AT (1) ATE395937T1 (de)
AU (1) AU2003217467B2 (de)
BR (1) BR0308117A (de)
CA (1) CA2475534C (de)
CY (1) CY1108268T1 (de)
DE (1) DE60321142D1 (de)
DK (1) DK1482981T3 (de)
ES (1) ES2302917T3 (de)
HK (1) HK1078462A1 (de)
IT (1) ITRM20020128A1 (de)
MX (1) MXPA04008639A (de)
PL (1) PL372721A1 (de)
PT (1) PT1482981E (de)
SI (1) SI1482981T1 (de)
TW (1) TWI345982B (de)
WO (1) WO2003075960A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334076D1 (de) 2002-02-26 2010-10-21 Sigma Tau Ind Farmaceuti Monoklonaler anti-mensch-tenascin-Antikörper
ITRM20020128A1 (it) * 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
JP2008064475A (ja) * 2006-09-04 2008-03-21 Osaka Univ 標的物質の高感度検出方法、検出用キットおよび検出装置
EP2941243A4 (de) 2013-01-04 2016-09-14 Massachusetts Inst Technology Oberflächenbindung bei der verabreichung eines arzneimittels auf nanopartikelbasis in ein gewebe
CN105214843A (zh) * 2015-10-20 2016-01-06 东莞市利发爱尔空气净化系统有限公司 一种高压放电单元及空气净化器

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687732A (en) * 1983-06-10 1987-08-18 Yale University Visualization polymers and their application to diagnostic medicine
JPH07507804A (ja) * 1992-06-09 1995-08-31 ネオルックス　コーポレーション 予備標的化方法及び化合物
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
ITRM20020128A1 (it) * 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
MXPA04008639A (es) 2004-12-06
ES2302917T3 (es) 2008-08-01
PL372721A1 (en) 2005-07-25
ITRM20020128A0 (it) 2002-03-08
ATE395937T1 (de) 2008-06-15
US20090010839A1 (en) 2009-01-08
CN1638807A (zh) 2005-07-13
CA2475534A1 (en) 2003-09-18
US7807133B2 (en) 2010-10-05
KR100993626B1 (ko) 2010-11-11
US20050106102A1 (en) 2005-05-19
PT1482981E (pt) 2008-07-15
CN1638807B (zh) 2010-05-26
AR038897A1 (es) 2005-02-02
DK1482981T3 (da) 2008-09-01
SI1482981T1 (sl) 2008-08-31
JP2005529081A (ja) 2005-09-29
BR0308117A (pt) 2005-01-04
AU2003217467A1 (en) 2003-09-22
JP4362376B2 (ja) 2009-11-11
EP1482981A1 (de) 2004-12-08
WO2003075960A1 (en) 2003-09-18
US7425317B2 (en) 2008-09-16
CY1108268T1 (el) 2014-02-12
AU2003217467B2 (en) 2008-06-26
ITRM20020128A1 (it) 2003-09-08
HK1078462A1 (en) 2006-03-17
TWI345982B (en) 2011-08-01
CA2475534C (en) 2011-06-14
TW200306207A (en) 2003-11-16
EP1482981B1 (de) 2008-05-21
KR20040093067A (ko) 2004-11-04

Similar Documents

Publication Publication Date Title
CY2015018I1 (el) Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων
DE50210454D1 (de) Einpark- und/oder Rangierhilfeeinrichtung
DK1501534T5 (da) Desmopressin i orodispergerbar dosisform
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
DE60325967D1 (de) Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen
DE60334131D1 (de) Acrylkautschukzusammensetzung und vernetztes objekt
SE0203497L (sv) Anordning avsedd att ingå i framställning av kolfiberförstärkt tandprotes
DE60212739D1 (de) Verbesserungen in oder in Bezug auf Mopwringer
ITBO20020487A0 (it) Contenitore e metodo per la realizzazione dello stesso
DE60310750D1 (de) Einheit zum überführen und zum einstellen der zwischenräume von gegenständen
DE60321142D1 (de) Zur erhöhung der konzentration von radioaktivem biotin bei der pretargeted radioimmuntherapie wirksame avidindimere
DE60318819D1 (de) Hitzestabile mutanten von stärkebiosyntheseenzymen
DE60215392D1 (de) Gerät mit reduzierten abmessungen und verbesserter ergonomie zur behandlung der oberfläche von objekten
DE60104935D1 (de) Zellenradschleuse zum konstanten Austrag von Kunstschnee
GB2410209B (en) Improvements in or relating to devices
GB0307150D0 (en) Improvements in or relating to the treatment of molten materials
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
DE60226710D1 (de) Kombination von docetaxel mit flavopiridol
FI20031458A (fi) Kantopakkaus ja pakkauksen kantorakenne
DE50301665D1 (de) Torblatthandgriff sowie Verwendung desselben
FI20021792A (fi) Jousi- ja kielisoitinrakenne
GB2396117B (en) Improvements relating to the construction of playing surfaces
DE60216986D1 (de) Neue verwendung von pipatalin
DE60013097D1 (de) Einheit zur Bestimmung der Wirksamkeit der Stimulation in einem Herzschrittmacher

Legal Events

Date Code Title Description
8364 No opposition during term of opposition